Proteases, Extracellular Matrix, and Cancer: A Workshop of the Path B Study Section

American Journal of Pathology

Volumn 164, Issue 4, 2004, Pages 1131-1139

  DeClerck, Yves A ^a,k   Mercurio, Arthur M ^b   Stack, M Sharon ^c   Chapman, Harold A ^d   Zutter, Mary M ^e   Muschel, Ruth J ^f   Raz, Avraham ^g   Matrisian, Lynn M ^e   Sloane, Bonnie F ^g   Noel, Agnes ^h   Hendrix, Mary J ⁱ   Coussens, Lisa ^d   Padarathsingh, Martin ^j  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF LIÈGE   (Belgium)

ⁱ UNIVERSITY OF IOWA   (United States)

^j NATIONAL INSTITUTES OF HEALTH   (United States)

^k CHILDREN S HOSPITAL LOS ANGELES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; GROWTH FACTOR RECEPTOR; PROTEINASE;

CANCER; CANCER INVASION; CELL INTERACTION; CELL PROLIFERATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; MICROENVIRONMENT; MOLECULAR BIOLOGY; MORPHOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; REGULATORY MECHANISM; REVIEW; STROMA CELL; TUMOR CELL;

EID: 12144285600     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63200-2     Document Type: Review

References (48)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70
2. Liotta LA, Kohn EC: The microenvironment of the tumour-host interface. Nature 2001, 411:375-379
3. Savagner P: Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001, 23:912-923
4. Bates RC, Mercurio AM: Tumor necrosis factor-α stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 2003, 14:1790-1800
5. Mercurio AM, Rabinovitz I: Towards a mechanistic understanding of tumor invasion: lessons from the α6β4 integrin. Semin Cancer Biol 2001, 11:129-141
6. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, Marinkovich MP, Tao S, Lin Q, Kubo Y, Khavari PA: NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003, 421:639-643
7. Rabinovitz I, Toker A, Mercurio AM: Protein kinase C-dependent mobilization of the α6β4 integrin from hemidesmosomes and its association with actin-rich cell protrusions drive the chemotactic migration of carcinoma cells. J Cell Biol 1999, 146:1147-1160
8. Shaw LM, Rabinovitz I, Wang HH, Toker A, Mercurio AM: Activation of phosphoinositide 3-OH kinase by the α6β4 integrin promotes carcinoma invasion. Cell 1997, 91:949-960
9. O'Connor KL, Shaw LM, Mercurio AM: Release of cAMP gating by the α6β4 integrin stimulates lamellae formation and the chemotactic migration of invasive carcinoma cells. J Cell Biol 1998, 143:1749-1760
10. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, Mercurio AM: Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001, 61:5736-5740
11. Bachelder RE, Ribick MJ, Marchetti A, Falcioni R, Soddu S, Davis KR, Mercurio AM: p53 inhibits α6β4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. J Cell Biol 1999, 147:1063-1072
12. Ghosh S, Brown R, Jones JC, Ellerbroek SM, Stack MS: Urinary-type plasminogen activator (uPA) expression and uPA receptor localization are regulated by α3β1 integrin in oral keratinocytes. J Biol Chem 2000, 275:23869-23876
13. Munshi HG, Ghosh S, Mukhopadhyay S, Wu YI, Sen R, Green KJ, Stack MS: Proteinase suppression by E-cadherin-mediated cell-cell attachment in pre-malignant oral keratinocytes. J Biol Chem 2002, 277:38159-38167
14. Munshi HG, Wu YI, Ariztia EV, Stack MS: Calcium regulation of matrix metalloproteinase-mediated migration in oral squamous cell carcinoma cells. J Biol Chem 2002, 277:41480-41488
15. Kugler MC, Wei Y, Chapman HA: Urokinase receptor and integrin interactions. Curr Pharm Des 2003, 9:1565-1574
16. Wei Y, Eble JA, Wang Z, Kreidberg JA, Chapman HA: Urokinase receptors promote β1 integrin function through interactions with integrin α3β1. Mol Biol Cell 2001, 12:2975-2986
17. Zhang F, Tom C, Kugler M, Ching T, Kreidberg J, Wei Y, Chapman HA: Distinct ligand binding sites in integrin a3b1 regulate matrix adhesion and cell:cell contact. J Cell Biol 2003, 163:177-188
18. He L, Pappan LK, Grenache DG, Li Z, Tollefsen DM, Santoro SA, Zutter MM: The contributions of the α2β1 integrin to vascular thrombosis in vivo. Blood 2003
19. Chen J, Diacovo TG, Grenache DG, Santoro SA, Zutter MM: The α(2) integrin subunit-deficient mouse: a multifaceted phenotype including defects of branching morphogenesis and hemostasis. Am J Pathol 2002, 161:337-344
20. Wong CW, Song C, Grimes MM, Fu W, Dewhirst MW, Muschel RJ, Al Mehdi AB: Intravascular location of breast cancer cells after spontaneous metastasis to the lung. Am J Pathol 2002, 161:749-753
21. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A, Kubo T: Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 1999, 85:2475-2484
22. Honjo Y, Nangia-Makker P, Inohara H, Raz A: Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 2001, 7:661-668
23. Inohara H, Raz A: Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 1994, 11:527-532
24. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A: Galectin-3: a novel anti-apoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997, 57:5272-5276
25. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A: Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002, 277:6852-6857
26. Rudolph-Owen LA, Matrisian LM: Matrix metalloproteinases in remodeling of the normal and neoplastic mammary gland. J Mammary Gland Biol Neoplasia 1998, 3:177-189
27. Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M: Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001, 114:111-118
28. Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM: Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 2001, 3:459-468
29. Vargo-Gogola T, Crawford HC, Fingleton B, Matrisian LM: Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch Biochem Biophys 2002, 408:155-161
30. Vargo-Gogola T, Fingleton B, Crawford HC, Matrisian LM: Matrilysin (matrix metalloproteinase-7) selects for apoptosis-resistant mammary cells in vivo. Cancer Res 2002, 62:5559-5563
31. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392
32. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174
33. Sameni M, Moin K, Sloane BF: Imaging proteolysis by living human breast cancer cells. Neoplasia 2000, 2:496-504
34. Sameni M, Dosescu J, Sloane BF: Imaging proteolysis by living human glioma cells. Biol Chem 2001, 382:785-788
35. Sameni M, Dosescu J, Moin K, Sloane BF: Functional imaging of proteolysis: stromal and inflammatory cells increase tumor proteolysis. Mol Imaging 2003, 2:1-17
36. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Noel A, Foidart JM: The pro- or anti-angiogenic effect of plasminogen activator inhibitor 1 is dose dependent. EMBO J 2002, 16:147-154
37. Sounni NE, Janssen M, Foidart JM, Noel A: Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol 2003, 22:55-61
38. Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, Gilles C, Deroanne C, Thompson EW, Foidart JM, Noel A: MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. EMBO J 2002, 16:555-564
39. Hajitou A, Sounni NE, Devy L, Grignet-Debrus C, Lewalle JM, Li H, Deroanne CF, Lu H, Colige A, Nusgens BV, Frankenne F, Maron A, Yeh P, Perricaudet M, Chang Y, Soria C, Calberg-Bacq CM, Foidart JM, Noel A: Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res 2001, 61:3450-3457
40. Remacle A, McCarthy K, Noel A, Maguire T, McDermott E, O'Higgins N, Foidart JM, Duffy MJ: High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000, 89:118-121
41. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998, 4:923-928
42. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM, Noel A: The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for anti-angiogenic strategies. J Cell Biol 2001, 152:777-784
43. Isogai C, Laug WE, Shimada H, Declerck PJ, Stins MF, Durden DL, Erdreich-Epstein A, DeClerck YA: Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res 2001, 61:5587-5594
44. Hendrix MJ, Seftor EA, Hess AR, Seftor RE: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003, 3:411-421
45. Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, Stetler-Stevenson WG, Quaranta V, Hendrix MJ: Cooperative interactions of laminin 5 γ2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001, 61:6322-6327
46. Seftor EA, Meltzer PS, Schatteman GC, Gruman LM, Hess AR, Kirschmann DA, Seftor RE, Hendrix MJ: Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit Rev Oncol Hematol 2002, 44:17-27
47. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D: Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999, 13:1382-1397
48. Coussens LM, Tinkle CL, Hanahan D, Werb Z: MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490